Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

吉利德科学（Gilead Sciences）与Kymera ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

吉利德科学公司（Gilead Sciences，NASDAQ:GILD）董事长兼首席执行官丹尼尔·奥戴（Daniel O’Day）于2025年6月30日售出了10,000股公司股票，总价值约110万美元。此次出售分两笔交易完成。目前，吉利德市值为1388.7亿美元，过去一年的回报率达68%，显示出强劲的发展势头。

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.